Helicobacter Pylori Diagnostics - Global Market Trajectory & Analytics

Global Helicobacter Pylori Diagnostics Market to Reach $729.2 Million by 2027

Amid the COVID-19 crisis, the global market for Helicobacter Pylori Diagnostics estimated at US$489.2 Million in the year 2020, is projected to reach a revised size of US$729.2 Million by 2027, growing at a CAGR of 5.9% over the period 2020-2027. Invasive, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$341.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Invasive segment is readjusted to a revised 6.3% CAGR for the next 7-year period.



The U. S. Market is Estimated at $132.5 Million, While China is Forecast to Grow at 8.9% CAGR

The Helicobacter Pylori Diagnostics market in the U. S. is estimated at US$132.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$153.3 Million by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR. We bring years of research experience to this 5th edition of our report. The 278-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Cardinal Health, Inc.
• DiaSorin SpA
• Exalenz Bioscience Ltd.
• F. Hoffmann-La Roche AG
• Halyard Health, Inc.
• Meridian Bioscience, Inc.
• Quidel Corporation
• Thermo Fisher Scientific, Inc.